A landmark randomized controlled trial published in npj Digital Medicine on February 3, 2026, demonstrated that the digital intervention mylovia produces clinically meaningful improvements in sexual functioning for women with sexual dysfunction — with effect sizes rivaling traditional in-person psychotherapy.

Why It Matters

Mylovia's RCT results address one of the largest unmet needs in sexual healthcare: the gap between the prevalence of female sexual dysfunction (affecting up to 40% of women globally) and the availability of affordable, accessible treatment. If approved as a DiGA in Germany, mylovia would become one of the first prescription digital therapeutics specifically for sexual dysfunction — a model that could be replicated in other markets.

The trial, conducted by researchers from GAIA (Hamburg), the Institute for Sexual, Psycho- and Trauma Therapy (Munich), the University of Lubeck, and the Medical School Hamburg, enrolled 252 women aged 18 and above with diagnosed sexual dysfunction. After three months of using mylovia alongside standard treatment, the intervention group showed a statistically significant and clinically relevant improvement in sexual function compared to controls, with a medium-sized between-group effect (Cohen's d = 0.51; p < 0.001). Improvements were maintained at the six-month follow-up.

Mylovia's therapeutic framework is based on Mindfulness-Based Therapy (MBT), a subtype of Cognitive Behavioral Therapy. The self-guided digital intervention uses a virtual dialogue system delivering focused information segments, with users selecting responses matching their situations to create what researchers describe as "a dynamic that mirrors actual conversation." The program covers psychoeducation, relaxation and mindfulness exercises, self-esteem strategies, sensate focus exercises, and strategies for managing desire discrepancy in relationships.

Led by sex therapist Wiebke Blaszcyk, the study found significant improvements not only in overall sexual function but specifically in sexual desire, sexual satisfaction, and pain-related cognitions and behaviors. Based on these results, mylovia has been submitted to Germany's Federal Institute for Drugs and Medical Devices (BfArM) for approval as a Digital Health Application (DiGA), which would make it prescribable by doctors and reimbursable through Germany's healthcare system.

Sources

Update — 2026-03-14

Initial entry — story first created.